Primary Pancreatic Lymphoma: What We Need to Know
Total Page:16
File Type:pdf, Size:1020Kb
757 Review Article Primary pancreatic lymphoma: what we need to know Neda Rad1, Alireza Khafaf2, Amir Houshang Mohammad Alizadeh3 1Research Institute for Gastroenterology and Liver Diseases, 2Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3Shahid Beheshti University of Medical Sciences, Taleghani Hospital, Tehran, Iran Contributions: (I) Conception and design: All authors; (II) Administrative support: AH Mohammad Alizadeh; (III) Provision of study material or patients: AH Mohammad Alizadeh, N Rad; (IV) Collection and assembly of data: N Rad, A Khafaf; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Prof. Amir Houshang Mohammad Alizadeh. Shahid Beheshti University of Medical Sciences, Taleghani Hospital, Parvaneh Ave, Tabnak Str, Evin, Tehran 19857, Iran. Email: [email protected]. Abstract: Hodgkin’s lymphoma is a group of malignant lymphoid which involve various organs including gastrointestinal tract. Stomach and small intestine are commonly involved more; however, pancreas can be primarily involved as well. The secondary involvement of pancreas caused by Hodgkin’s lymphoma is more prevalent than the primarily involvement (1 .25–2.2% vs. <1%). Primary pancreatic lymphomas (PPLs) consist of 1–2% of all lymphoma outside nods. The symptoms and findings of PPL imaging can be akin to that of pancreas adenocarcinoma and differentiating them is difficult without examining the tissue sample. The prognosis and treatment of PPL are different from those of adenocarcinoma and due to the superior prognosis of PPL compared to pancreas adenocarcinoma, the proper diagnosis of the disease is important. Keywords: Pancreas; lymphoma; adenocarcinoma Submitted Mar 11, 2017. Accepted for publication May 18, 2017. doi: 10.21037/jgo.2017.06.03 View this article at: http://dx.doi.org/10.21037/jgo.2017.06.03 Introduction to obtain tissue samples through endoscopic ultrasound in recent years (2). Non-hodgkin’s lymphoma (NHL) is a group of malignant lymphoids which can be seen at any age. It is often determined with enlarged lymph nodes, fever, and weight Epidemiology loss. NHL commonly affects extranodal organs while PPL consists of approximately 1% of all extranodal the involvement of pancreas is primarily rare and can be lymphomas and 5% of all pancreatic masses (1). PPLs are with or without the involvement of lymph nodes around more common in males (58%) and are usually seen in the the pancreas (1). Differentiation of primary pancreatic 5th or 6th decades of life. lymphoma (PPL) and adenocarcinoma is important due The most histological type of PPL is diffuse large B cell to different treatment and better prognosis; however, lymphoma which forms 80% of all cases, however, other the symptoms of PPL are not specific and can mimic histologic types may rarely be seen (3). adenocarcinoma. PPL can often be seen as a mass larger Rad et al. (4) reported on patient with pancreatic mass than 5 cm in the pancreas while unlike adenocarcinoma, no and icter who had low grade B cell lymphoma in the vascular involvement is commonly observed. The definitive histological examination (Figures 1 and 2). diagnosis of PPL is impossible based on imaging and it requires pathological examination. CT-guided biopsy Clinical symptoms and laparotomy have been proposed for obtaining tissue samples. Fine needle aspiration (FNA) through endoscopic Clinical symptoms of PPL are not specific for the disease ultrasound (EUS) (EUS-FNA) has been a good method and include epigastric pain, abdominal mass, weight loss, © Journal of Gastrointestinal Oncology. All rights reserved. jgo.amegroups.com J Gastrointest Oncol 2017;8(4):749-757 750 Rad et al. PPL: what we need to know A B Figure 1 Low grade B cell lymphoma (hematoxylin-eosin stain; original magnification ×200). A B Figure 2 CD20-BCL2-CD10-CD43-CD3 positive atypical lymphocytic cells (immunohistochemistry; magnification, ×25). jaundice, nausea, vomiting, diarrhea, pancreatitis, and (IV) Pancreatic mass specified in surgery with the intestinal obstruction (5,6). involvement of lymph nodes confined to the PPLs rarely represent B symptoms which are often seen pancreas; in other lymphoma and include fever, night sweats, and (V) Lack of involvement of liver or spleen. weight loss. The most symptoms of PPLs are with vague abdominal discomforts such as dyspepsia, pain, nausea, Imaging techniques vomiting, feeling of fullness, and body weight loss (7). Dawson et al. proposed five criteria for the diagnosis of Transabdominal ultrasound (TUS) PPL (8): TUS is a technique dependent on the accuracy of operator (I) Lack of peripheral lymphadenopathy; and has a low precision to see small masses in the head of the (II) Lack of involvement of mediastinal lymph node; pancreas. TUS can indicate dilatation and obstruction of the (III) Counting normal peripheral white blood cells; bile ducts and liver metastases (9). Using new methods of © Journal of Gastrointestinal Oncology. All rights reserved. jgo.amegroups.com J Gastrointest Oncol 2017;8(4):749-757 Journal of Gastrointestinal Oncology Vol 8, No 4 August 2017 751 ultrasound such as Color-power Doppler us, 3 dimensional and focal nodular in T1W1 images and high or low signal (3D) US, and harmonic imaging, contrast-enhanced us, the intensity in T2W1 images. In DCE-MRI, low enhanced diagnosis of pancreatic masses has significantly enhanced (10). area surrounded by parenchyma is usually observed (5,18). Using contrast enhanced us, vascular involvement can Unlike CT, the lesions of pancreatic lymphoma are mildly be investigated in the pancreas masses that can help the heterogeneous in MRI, especially in T2W images. Tumors differentiation of pancreatic masses (11). of Islet cell have more hyper intensity than lymphoma in T2w images. Whole body DW1 had formerly a significant role in Abdominal CT scan diagnosing and staging the disease in lymphoma patients. To examine pancreas masses and liver metastases, CT scan By receiving intravenous gadolinium contrast, lymphoma which is an accessible and noninvasive method can be used is homogeneously enhanced in a less degree than normal and based on the results of CT scan, decisions can be made parenchyma. A number of lymphomas appear softly on sampling to prove the diagnosis. The quality of CT inhomogeneous in MRI. Due to the desmoplastic content, scan images has been improved using multiple detector CT the pancreas adenocarcinoma is less enhanced and after which creates images with high resolution 3-D imaging receiving gadolinium, they are typically inhomogeneous. and multiplanar ones. Rapid injection of iodine-containing Due to the difference in the treatment and prognosis of contrast and images that are immediately taken after pancreatic lymphoma, its differentiation from similar injection are among the methods to increase the sensitivity lesions such as pancreatic autoimmune and autoimmune of CT in the evaluation of pancreatic masses (11). CT pancreatitis seems to be of great significance (20). sensitivity is low for lesions less than 2 cm (12-14). Merkle et al. (5) offered the following criteria for CT scan guide can be used for the biopsy of pancreatic distinguishing lymphoma from pancreatic autoimmune: lesions with the sensitivity about 95% (15,16). Radiological (I) Huge homogeneous mass without cystic-necrosis results from the previous studies in which the secondary lesions or MPD involvement; lymphoma of the pancreas was similar to primary lymphoma (II) Adjacent arteries involvement without obstruction; include nodular, diffuse and multinodular (6,17,18). Most (III) If there were lymphadenopathy under the left renal masses have been recognized through intravenous injection vein, it would be limited to the area around the by CT scan well and sometimes are bulky and infiltrated. pancreas. Lesions with the homogeneous low attenuation are along However, despite the above criteria, CT-guided biopsy with a slight enhancement of pancreatic parenchyma (5). or EUS FNA is important for an accurate diagnosis in most Pancreatic lymphoma with a lower incidence may show cases. the symptoms of acute pancreatitis on CT scan which appears as diffuse pancreatic enlargement while the results EUS of typical pancreatitis in CT including inflammation around the pancreas or fat stranding do not exist; otherwise, they Although EUS is dependent on operator, it is more can be seen usually minimal. Fluid accumulation around sensitive than CT or MRI to detect suspicious pancreatic the pancreas, pancreatic fat necrosis and rupture of the lesions or lesions less than 2 cm on CT if it is done by an pancreatic duct are not seen in lymphoma. Vascular experienced person (12,14,21-23). Tissue sampling by EUS involvement by tumor can rarely be seen in lymphoma (5). can be done in two ways: either by EUS guided FNA (EUS- Although pressure may be observed on vessels due to the FNA) or EUS guided fine-needle core biopsy (EUS-FNB). effect of the mass, there are no changes resulting from the The sensitivity of EUSFNA is 95% and its specificity is conflict involvement of tumor including a change in caliber 100% (24-27). It is the preferred method for sampling and irregularity (19). the pancreatic tissue, especially when the biopsy results of other methods are negative or ambiguous for malignancy (28,29). Although EUSFNA along with cytopathology are MRI usually suitable for the diagnosis of adenocarcinoma and MRI is